KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-cash Items: 2010-2017

  • Biomarin Pharmaceutical's Non-cash Items fell 97.82% to $6.6 million in Q4 2017 from the same period last year, while for Dec 2017 it was $6.6 million, marking a year-over-year decrease of 97.82%. This contributed to the annual value of $281.1 million for FY2017, which is 3858.05% up from last year.
  • According to the latest figures from Q4 2017, Biomarin Pharmaceutical's Non-cash Items is $6.6 million, which was down 97.82% from $304.4 million recorded in Q4 2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Non-cash Items peaked at $630.9 million during Q4 2015, and registered a low of $6.6 million during Q4 2017.
  • Over the past 3 years, Biomarin Pharmaceutical's median Non-cash Items value was $304.4 million (recorded in 2016), while the average stood at $314.0 million.
  • In the last 5 years, Biomarin Pharmaceutical's Non-cash Items soared by 5,375.75% in 2013 and then slumped by 97.82% in 2017.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Non-cash Items stood at $477.6 million in 2013, then rose by 25.65% to $600.1 million in 2014, then climbed by 5.14% to $630.9 million in 2015, then tumbled by 51.76% to $304.4 million in 2016, then crashed by 97.82% to $6.6 million in 2017.
  • Its last three reported values are $6.6 million in Q4 2017, $304.4 million for Q4 2016, and $630.9 million during Q4 2015.